An evaluation of the cost-effectiveness of duloxetine as a treatment for women with moderate-to-severe stress urinary incontinence

Journal of Medical Economics

Volumn 9, Issue 1-25, 2006, Pages 1-25

  Das Gupta, Roben ^a   Caiado, Maria ^a   Bamber, Luke ^a  

^a BOEHRINGER INGELHEIM LTD   (United Kingdom)

Author keywords

Cost effectiveness; Drug therapy; Duloxetine; Economic evaluation; Pelvic floor muscle training; Stress; Urinary incontinence

Indexed keywords

DULOXETINE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; HUMAN; PELVIC FLOOR MUSCLE TRAINING; STRESS INCONTINENCE; UNIVARIATE ANALYSIS;

EID: 33646061611     PISSN: 1369698X     EISSN: None     Source Type: Journal    
DOI: 10.3111/200609001025     Document Type: Article

References (42)

1. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourology and Urodynamics 2002; 21: 167-178.
2. Bump RC, Copeland Jr WE, Hurt WG et al. Dynamic urethral pressure/profilometry pressure transmission ratio determinations in stress-incontinent and stress-continent subjects. American Journal of Obstetrics and Gynecology 1988; 159: 749-755.
3. Hunskaar S, Lose G, Sykes D et al. The prevalence of urinary incontinence in women in four European countries. BJU International 2004; 93: 324-330.
4. Seim A, Sandvik H, Hermstad R et al. Female urinary incontinence - consultation behaviour and patient experiences: an epidemiological survey in a Norwegian community. Family Practice 1995; 12: 18-21.
5. Shaw C, Tansey R, Jackson C et al. Barriers to help seeking in people with urinary symptoms. Family Practice 2001; 18: 48-52.
6. Shaw C, Das Gupta R, Dallosso H et al. The current extent and impact of stress urinary incontinence symptoms in women who had previously sought help with a healthcare professional (Abstract). Presented at International Continence Society - UK Conference; Leicester, UK; 2003 April 24-25.
7. Hay-Smith EJ, Bo Berghmans LC, Hendriks HJ et al. Pelvic floor muscle training for urinary incontinence in women. Cochrane Database of Systematic Reviews 2001;1:CD001407.
8. Wilson PD, Bø K, Hay-Smith J et al. Conservative treatment in women. In: Abrams P, Shoury S, Wein A, Editors. Incontinence, 2nd edn. Plymouth, UK: Health Publication Ltd., 2002: 571-624.
9. Lagro-Janssen T, Van Weel C. Long-term effect of treatment of female incontinence in general practice. British Journal of General Practice 1998; 48: 1735-1738.
10. Adams EJ, Barrington JW, Brown K et al. Surgical treatment of urodynamic stress incontinence. Royal College of Obstetricians and Gynaecologists Guideline No. 35, October 2003. Available at: http://www.rcog.org.uk/index.asp?PageID=15 (accessed 4 April 2004).
11. Health Research Unit and Health Economics Research Unit, University of Aberdeen. Systematic review of the clinical effectiveness and cost-effectiveness of tension-free vaginal tape (TVT) for treatment of urinary stress incontinence. Report commissioned by NHS R&D HTA Programme on behalf of The National Institute for Clinical Excellence. Available at: http://www.nice.org. uk/pdf/ Assessment_report_TVT.pdf (accessed 7 May 2004).
12. Black NA, Downs SH. The effectiveness of surgery for stress incontinence in women: a systematic review. British Journal of Urology 1996; 78: 497-510.
13. Diokno AC, Burgio K, Fultz NH et al. The prevalence and outcomes of continence surgery among community-dwelling women. Journal of Urology 2003; 170: 507-511.
14. Bump R, Hooper C, Koke S et al. Worldwide efficacy of duloxetine after 12 weeks and 1 year in women with stress urinary incontinence (SUI): a 4-study meta-analysis. Poster presented at 33rd annual meeting of the International Continence Society (ICS); Florence, Italy; 5-9 October 2003 [Abstract 337]. Available at: http://www.continet.org/publications /2003/pdf/337.pdf (accessed 15 April 2004).
15. Norton P, Zinner NR, Yalcin I et al. Duloxetine versus placebo in the treatment of stress urinary incontinence. American Journal of Obstetrics and Gynecology 2002; 187: 40-48.
16. Dmochowski RR, Norton PA, Zinner NR et al. Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. Journal of Urology 2003; 170: 1259-1263.
17. Van Kerrebroeck P, Abrams P, Lange R et al. Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence. British Journal of Obstetrics and Gynaecology 2004; 111: 249-257.
18. Millard RJ, Moore K, Rencken R et al. Duloxetine versus placebo in the treatment of stress urinary incontinence: a four-continent randomised clinical trial. BJU International 2004; 93: 311-318.
19. Ghoniem G, Van Leeuwen JS, Elser DM et al. A randomised controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence. Journal of Urology 2005; 173: 1647-1653.
20. Kinchen KS, Obenchain R, Swindle R. The impact of duloxetine on quality of life for women with symptoms of urinary incontinence. International Urogynecology Journal and Pelvic Floor Dysfunction 2005; 16: 337-344.
21. Data on file. Eli Lilly and Company Ltd.
22. Department of Health. Good Practice in Continence Services. London, UK: Department of Health, 2000.
23. Scottish Intercollegiate Guidelines Network. Management of urinary incontinence in primary care, 2005. Available at http://www.sign.ac.uk/ guidelines/publishe d/ (accessed 28 June 2005).
24. National Institute for Health and Clinical Excellence. Urinary incontinence: the management of urinary incontinence in women. Guidelines and cancer service guidance in development. Available at: http://www.nice.org.uk/ page.aspx?o=guid elines.inprogress (accessed 1 July 2005).
25. Data on file: Moderate to Severe Patients in the Meta-analysis Studies. Eli Lilly & Company Ltd. and Boehringer Ingelheim, 2005.
26. Ward K, Hilton P; United Kingdom and Ireland Tension-free Vaginal Tape Trial Group. Prospective multicentre randomised trial of tension-free tape and colposuspension as primary treatment for stress incontinence. BMJ 2002; 325: 67-73.
27. Wagg AS, Bushnell D, Das Gupta RJ. Treatments received for stress urinary incontinence (SUI) symptoms by patients referred to secondary care within a UK setting. Poster presented at the International Continence Society (UK); Bournemouth, UK; 19 March 2004.
28. Department of Health. Hospital Episode Statistics. Health and Social Care Information Centre, 2003/2004.
29. Kinchen KS, Obenchain R, Swindle R. Impact of duloxetine on quality of life for women with symptoms of urinary incontinence. International Urogynecology Journal and Pelvic Floor Dysfunction 2005; 16: 337-344.
30. Manikandan R, Kujawa M, Pearson E et al. Results of the tension-free vaginal tape procedure for stress incontinence: patient's perspective. International Journal of Urology 2004; 11: 206-212.
31. Kobelt G. Economic considerations and outcome measurement in urge incontinence. Urology 1997; 50 (Suppl 6A): 100-107.
32. Manca A, Sculpher MJ, Ward K et al. A cost-utility analysis of tension-free tape versus colposuspension for primary urodynamic stress incontinence. British Journal of Obstetrics and Gynaecology 2003; 110: 255-262.
33. Das Gupta R, Wagg A, Porkess S et al. A description of the healthcare provision received by women with urinary incontinence seeking help for their symptoms in the UK and Republic of Ireland. ICS (UK) 12th Annual Scientific Meeting; Glasgow, UK; 31 March - 1 April 2005.
34. Yentreve Summary of Product Characteristics; November 2005.
35. Lalos O. Quality of life: a Marshall-Marchetti-Krantz procedure for stress urinary incontinence. Journal of Urology 1996; 155: 259-262.
36. McAllister R, Das Gupta R, Piercy J et al. An analysis of patients on waiting lists to receive surgery for stress urinary incontinence (SUI) in England and Scotland. Presented at the International Society for Pharmacoeconomic and Outcomes Research; Hamburg, Germany; 24-26 October 2004.
37. NHS Reference Costs, 2004. Available at: http://www.doh.gov.uk (accessed 7 December 2005).
38. Personal Social Services Research Unit. Unit Costs of Health & Social Care, 2004.
39. MIMS. July 2005.
40. National Institute for Clinical Excellence. Guide to the methods of technology appraisal, April 2004. Available at: http://www.nice.org.uk (accessed 17 March 2005).
41. Lalos O, Berglund AL, Lalos A. Impact of urinary and climacteric symptoms on social and sexual life after surgical treatment of stress urinary incontinence in women: a long-term outcome. Journal of Advanced Nursing 2001; 33: 316-327.
42. Black N, Griffiths J, Pope C et al. Impact of surgery for stress incontinence on morbidity: cohort study. BMJ 1997; 315: 1493-1502.